Outcomes of surgery and subsequent therapy for central nervous system oligoprogression in EGFR-mutated NSCLC patients

Table 2 Univariate and multivariate analysis for overall survival

			Univariate				Multivariate
		N	OR	95% CI		p value	OR	95% CI		p value
				Lower	Upper			Lower	Upper
Age		37	0.99	0.95	1.032	0.646
Female		24	0.36	0.141	0.916	0.032	0.19	0.063	0.574	0.003
Smoking history		6	1.285	0.422	3.917	0.659
KPS		37	1.006	0.99	1.024	0.452
Extracranial metastasis present		16	1.08	0.446	2.617	0.865
EGFR mutation	19 del	11
	L858R	23	0.842	0.315	2.248	0.732
	Others	3	1.564	0.304	8.046	0.593
Tumor number	1	13
	2–3	24	0.811	0.339	1.943	0.639
Main tumor location	Supratentorial	30
	Infratentorial	7	1.943	0.704	5.368	0.2
Main tumor size		37	1.007	0.764	1.327	0.96
Treatment	Surgery	21
	WBRT	16	1.602	0.658	3.9	0.299
Subsequent therapy	Change TKI	24
	Keep TKI	8	2.095	0.722	6.078	0.174	3.476	1.057	11.429	0.04
	Chemotherapy	5	4.527	1.097	18.672	0.037	6.988	1.286	37.962	0.024
Oligoprogression type	Repeat or Metachronous	17
	Induced	20	3.525	1.335	9.306	0.011	3.346	1.177	9.517	0.024

Del 19, exon 19 deletion; KPS, Karnofsky performance scale; L858R, exon 21 L858R; Others, Exon 21 L861Q, Exon 18 G719X, and Exon 20 S768I; TKI, tyrosine kinase inhibitors; WBRT, whole brain radiation therapy

ISSN: 1477-7819